# IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

> **NCT03194815** · PHASE2 · RECRUITING · sponsor: **University of Cambridge** · enrollment: 70 (estimated)

## Conditions studied

- Psychosis
- Autoimmune Encephalitis

## Interventions

- **DRUG:** Intravenous immunoglobulin
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03194815
- **Lead sponsor:** University of Cambridge
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-01
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03194815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03194815, "IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03194815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*